IL2 and Miyoshi myopathy: Lenalidomide (Revlimid®) was invented to reduce toxicity and enhance efficiency of thalidomide, which can specifically inhibit the growth of mature B cell lymphomas (like MM) and induce IL-2 release from T cells (Table 1).403,404 In addition to anti-MM treatment, lenalidomide has been approved by FDA for mantle cell lymphoma (MCL) in 2013, because it demonstrated consistent efficacy and safety of heavily pretreated patients with advanced-stage relapsed/refractory MCL in multiple phase II trials.405